Reine

A secondary paper is a paper you do once you are done with your primary paper. I’ve been working on this for a long time and always have fun doing it.

In this episode, I am talking about the reasons why people stay in their comfort zones and always choose the “safe side”. And why choosing this hinders you from your personal and career growth.

I am really passionate about leadership and Claude Petit is also passionate about building leaders and being an effective leader. Together, we will share with you how to become a statistical leader, how to build an organization of leaders, her very interesting leadership journey, and what it actually means to be a Statistician.

My experience of working with pharmacometricians was very limited because I spent most of my time working more on the later phases. The contact with people in pharmacology in the later phases of the industry is not that big. That’s why I found this episode really helpful. If you don’t have a clue what happens in pharmacology, then stay tuned for this episode.

You got regulatory approval for a new indication earlier than expected. While the regulatory team celebrates the achievement you worry that you need to have your NMA ready 3 months earlier. Will you be able to deliver?

We discuss these and many more problems of NMAs.

In today’s episode, I am the interviewee, and Jenny is the one asking the questions. We are talking about how training in launch and commercialization can be a super weapon, what its role is, and how can training be developed and delivered successfully to non-statisticians.

Listen to this webinar while Emma and I talk about exploring the resulting recruitment challenges in a post-pandemic world within Life Sciences as a sector, also specifically within statistics across the UK and Europe. We confront recruitment challenges, as well as taking a thorough analysis into what Statisticians want—how to hire and how to keep top talent.